Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Vertex Pharmaceuticals (NQ:VRTX)

454.02 +6.64 (+1.48%)
Streaming Delayed Price Updated: 2:46 PM EST, Dec 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vertex Pharmaceuticals

< Previous 1 2
...
30 31 32 33 34 35 36 37 38
...
69 70 Next >
News headline image
MarketBeat Week in Review – 11/6 - 11/10
Stocks closed the week with a strong rally, but the rally may reverse when investors get the latest information about inflation and retail stocks next week 
Via MarketBeat
Topics Artificial Intelligence Economy
News headline image
3 Growth Stocks to Buy Right Now Without Any Hesitation ↗
Investors shouldn't have to deliberate for too long about these great stocks. 
Via The Motley Fool
News headline image
4 First-in-Their-Class Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip ↗
A 15% decline in the Nasdaq Composite is a red-carpet opportunity for investors to snag high-quality growth stocks at a discount. 
Via The Motley Fool
Topics Stocks
News headline image
Amphastar Pharmaceuticals Stock Earns Composite Rating Upgrade ↗
Amphastar Pharmaceuticals stock saw its IBD SmartSelect Composite Rating rise to 98 Friday, up from 93 the day before. 
Via Investor's Business Daily
News headline image
What 10 Analyst Ratings Have To Say About Vertex Pharmaceuticals ↗
 
Via Benzinga
News headline image
Earnings Scheduled For November 6, 2023 ↗
Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is expected to report quarterly earnings at $0.16 per share on revenue of $366.82 million. 
Via Benzinga
News headline image
Exploring NASDAQ:VRTX's quality characteristics. ↗
Reasonable Growth, Debt Levels, and a High ROIC Make VERTEX PHARMACEUTICALS INC (NASDAQ:VRTX) Appealing to Quality Investors. 
Via Chartmill
News headline image
Stock Market Rally Pauses As Yields Rebound; Datadog, Affirm Among Earnings Winners: Weekly Review ↗
The major indexes ended long win streaks. Datadog led earnings winners. 
Via Investor's Business Daily
News headline image
3 Biotech Stocks That Are Betting on the Future of Gene Editing ↗
These three companies have gene editing therapies in late-stage clinical trials, making them promising biotech stocks to buy right now. 
Via InvestorPlace
News headline image
This Program for a Common Problem May Be Vertex Pharmaceuticals' Ticket to a New Wave of Billion-Dollar Revenues ↗
Vertex shares look cheap today considering all the company has to offer. 
Via The Motley Fool
News headline image
Why you can make Vertex Pharmaceuticals a buy on any pullback
Vertex stock is off its all-time highs after a slight miss on revenue, but the company's robust pipeline gives investors a reason to watch VRTX stock closely 
Via MarketBeat
News headline image
4 Reasons to Worry About Vertex Pharmaceuticals -- Debunked ↗
No biotech stock is worry-free. But investors shouldn't fret about these four issues for Vertex. 
Via The Motley Fool
News headline image
Vertex Slouches After Tech Leader Reports Mixed Results; But Late-Stage Pipeline In Focus ↗
The company expects $9.85 billion in full-year sales of its cystic fibrosis treatments. 
Via Investor's Business Daily
News headline image
These Analysts Revise Their Forecasts On Vertex Pharmaceuticals After Q3 Results ↗
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) reported upbeat earnings for its third quarter, while sales missed estimates. 
Via Benzinga
Topics Earnings
News headline image
S&P 500, Nasdaq Set To Break 6-Day Rally Today? Traders Await Fed Cues, Analyst Says Seasonal Rally Has Started With Gusto ↗
Sentiment appears to have dipped after a six-session winning streak. Stock futures indicate a modestly lower opening on Tuesday as small and mid-cap earnings reports gain momentum. 
Via Benzinga
Topics Economy Stocks
News headline image
Vertex Pharmaceuticals (VRTX) Q3 2023 Earnings Call Transcript ↗
VRTX earnings call for the period ending September 30, 2023. 
Via The Motley Fool
Topics Earnings
News headline image
Vertex Reports Third Quarter 2023 Financial Results
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
Cathie Wood's ARK Innovation Just Had Its Best Week Ever Thanks To Roku, These Huge Winners ↗
Roku vaulted 50% to become Ark Innovation's top holding. 
Via Investor's Business Daily
News headline image
US Stocks Set To Extend 5-Day Winning Streak Today? Traders Anxiously Watch Fed Speech, Climbing Bond Yields ↗
The market looks set to extend last week’s gains, with the stock futures holding up early Monday ahead of a slew of earnings reports mostly from the small and mid-cap space. 
Via Benzinga
Topics Economy
News headline image
Fed Holds Rates Steady, Powell's Cautious Stance Soothes Investors, Labor Market Softens: The Week In The Markets ↗
Markets bounced back decisively this week, shrugging off prior volatile months marked by heightened geopolitical tensions. The resurgence of risk sentiment ignited a relief rally in both equities and... 
Via Benzinga
Topics Bonds Economy
News headline image
Stock Market Rally Back In Force As Treasury Yields Plunge; Arista, Palantir Among Winners: Weekly Review ↗
Bulls are back in control as the major indexes confirmed the uptrend this week. 
Via Investor's Business Daily
News headline image
Here's What Investors Need to Know About Vertex Pharmaceuticals and CRISPR Therapeutics' Big Day at the FDA ↗
The meeting went almost as well as could be expected. 
Via The Motley Fool
News headline image
Vertex to Present New Data on Exagamglogene Autotemcel (exa-cel) at the American Society of Hematology (ASH) Annual Meeting and Exposition
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
Vertex to Present Data Highlighting Long-Term Benefits of TRIKAFTA® at the North American Cystic Fibrosis Conference
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
One Month Ahead of its Most Crucial Moment Ever, Should You Buy CRISPR Therapeutics? ↗
This stock could be a long-term winner, thanks to its game-changing technology. 
Via The Motley Fool
News headline image
Here's How Much $100 Invested In Vertex Pharmaceuticals 10 Years Ago Would Be Worth Today ↗
 
Via Benzinga
News headline image
Crispr Therapeutics Rallies On Bullish Views Of First-Ever Gene-Editing Drug ↗
The agency could soon approve a potential cure for sickle cell disease . 
Via Investor's Business Daily
News headline image
Apellis Pharmaceuticals Stock Improves With An RS Ratings Over 90 ↗
Apellis Pharmaceuticals shows improving price performance, earning an upgrade to its IBD Relative Strength Rating. 
Via Investor's Business Daily
News headline image
Gene Therapy Could Be On the Cusp of a Major Breakthrough, but Investors May Have to Remain Patient ↗
This gene-editing pioneer could make history this week. But shareholders should remain focused on the long term. 
Via The Motley Fool
News headline image
Want $1 Million in Retirement? Invest $250,000 in These 3 Stocks and Wait a Decade ↗
4x returns in just a decade is quite an attainable result for these companies. 
Via The Motley Fool
< Previous 1 2
...
30 31 32 33 34 35 36 37 38
...
69 70 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.